HK1246303A1 - 反义抗菌化合物和方法 - Google Patents

反义抗菌化合物和方法 Download PDF

Info

Publication number
HK1246303A1
HK1246303A1 HK18105904.4A HK18105904A HK1246303A1 HK 1246303 A1 HK1246303 A1 HK 1246303A1 HK 18105904 A HK18105904 A HK 18105904A HK 1246303 A1 HK1246303 A1 HK 1246303A1
Authority
HK
Hong Kong
Prior art keywords
methods
antibacterial compounds
antisense
antisense antibacterial
compositions
Prior art date
Application number
HK18105904.4A
Other languages
English (en)
Chinese (zh)
Inventor
Bruce L. Geller
David Greenberg
Original Assignee
Oregon State University
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University, Board Of Regents, The University Of Texas System filed Critical Oregon State University
Publication of HK1246303A1 publication Critical patent/HK1246303A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK18105904.4A 2014-12-31 2015-12-23 反义抗菌化合物和方法 HK1246303A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098713P 2014-12-31 2014-12-31
US62/098,713 2014-12-31
PCT/US2015/000280 WO2016108930A2 (en) 2014-12-31 2015-12-23 Antisense antibacterial compounds and methods

Publications (1)

Publication Number Publication Date
HK1246303A1 true HK1246303A1 (zh) 2018-09-07

Family

ID=56285129

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105904.4A HK1246303A1 (zh) 2014-12-31 2015-12-23 反义抗菌化合物和方法

Country Status (7)

Country Link
US (1) US11293024B2 (https=)
EP (1) EP3240794A4 (https=)
JP (2) JP6994941B2 (https=)
AU (1) AU2015372560B2 (https=)
CA (2) CA3249464A1 (https=)
HK (1) HK1246303A1 (https=)
WO (1) WO2016108930A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790495B2 (en) 2014-05-16 2017-10-17 Oregon State University Antisense antibacterial compounds and methods
AU2015264449B2 (en) 2014-05-19 2022-05-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
CA3249464A1 (en) 2014-12-31 2025-11-29 Univ Texas Antisense antibacterial compounds and methods
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2020035619A1 (en) * 2018-08-17 2020-02-20 Centre National De La Recherche Scientifique (Cnrs) Rna-based biocontrol methods to protect plants against pathogenic bacteria and / or promote beneficial effects of symbiotic and commensal bacteria
GB2579253A (en) 2018-11-28 2020-06-17 Pedanius Therapeutics Ltd Antibacterial antisense agents

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668616A (en) * 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
JP3022967B2 (ja) 1985-03-15 2000-03-21 アンチバイラルズ インコーポレイテッド 立体規則性ポリヌクレオチド結合ポリマー
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
WO1993001286A2 (en) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
ATE330644T1 (de) 1995-12-18 2006-07-15 Angiotech Biomaterials Corp Vernetzten polymerisatmassen und verfahren für ihre verwendung
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
WO1998050557A1 (en) * 1997-05-02 1998-11-12 University Of Guelph Proteins involved in the synthesis and assembly of core lipopolysaccharide of pseudomonas aeruginosa
WO2000015265A1 (en) * 1998-09-16 2000-03-23 Vitagenix, Inc. Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
US20040033972A1 (en) * 2000-12-20 2004-02-19 Horwitz Marcus A. Treatment of mycobacterium tuberculosis with antisense polynucleotides
US20060241075A1 (en) 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2004231740A1 (en) 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
ATE510914T1 (de) 2004-07-02 2011-06-15 Avi Biopharma Inc Antisinn antibakterielle verfahren und verbindungen
US20060263798A1 (en) 2005-02-11 2006-11-23 International Business Machines Corporation System and method for identification of MicroRNA precursor sequences and corresponding mature MicroRNA sequences from genomic sequences
US7790694B2 (en) 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CA2614191C (en) 2005-07-13 2015-06-30 Avi Biopharma, Inc. Antisense antibacterial method and compound
WO2007025016A1 (en) 2005-08-25 2007-03-01 Texas Tech University System Inhibition of metallo-beta-lactamase by double-stranded dna
EP3443976A1 (en) * 2007-06-29 2019-02-20 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
MX2010004955A (es) 2007-11-15 2010-06-30 Avi Biopharma Inc Metodo de sintesis de oligomeros de morfolina.
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2009139635A1 (en) * 2008-05-15 2009-11-19 Prosensa Technologies B.V. Polymyxin derivatives and uses thereof
WO2010134939A2 (en) * 2008-12-19 2010-11-25 Zirus, Inc. Mammalian genes involved in infection
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011018798A2 (en) 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
EP3067420A1 (en) 2010-11-12 2016-09-14 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
US20120213663A1 (en) 2011-02-23 2012-08-23 King Fahd University Of Petroleum And Minerals Method of removing e. coli bacteria from an aqueous solution
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
KR101317263B1 (ko) 2011-07-05 2013-10-10 (주)지노첵 리얼타임 pcr을 이용한 카바페넴 내성 장내균 검사 방법 및 키트
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
EA202090338A1 (ru) * 2011-11-18 2021-04-30 Сарепта Терапьютикс, Инк. Функционально-модифицированные олигонуклеотиды и их субъединицы
KR101450751B1 (ko) * 2012-07-05 2014-10-16 서강대학교산학협력단 미생물을 이용한 지방산 제조 방법
US9790495B2 (en) 2014-05-16 2017-10-17 Oregon State University Antisense antibacterial compounds and methods
AU2015264449B2 (en) 2014-05-19 2022-05-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
CA3249464A1 (en) 2014-12-31 2025-11-29 Univ Texas Antisense antibacterial compounds and methods
AU2016379399B2 (en) 2015-12-23 2022-12-08 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods

Also Published As

Publication number Publication date
EP3240794A4 (en) 2018-10-31
US11293024B2 (en) 2022-04-05
WO2016108930A3 (en) 2016-08-25
AU2015372560A1 (en) 2017-07-20
JP2022040131A (ja) 2022-03-10
EP3240794A2 (en) 2017-11-08
CA2972653C (en) 2025-05-06
WO2016108930A2 (en) 2016-07-07
CA2972653A1 (en) 2016-07-07
JP2018506272A (ja) 2018-03-08
CA3249464A1 (en) 2025-11-29
JP6994941B2 (ja) 2022-02-04
US20190169609A1 (en) 2019-06-06
AU2015372560B2 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
HK1246303A1 (zh) 反义抗菌化合物和方法
EP3577127A4 (en) TARGETED OLIGONUCLEOTIDES
EP3326661B8 (en) Bio-ink composition having improved physical and biological properties
EP3368086A4 (en) SKIN ADHESIVES, ANTIMICROBIAL COMPOSITIONS, ARTICLES AND METHODS OF USE THEREOF
HK1254843B (zh) 包含细菌菌株的组合物
WO2013120022A3 (en) Treatment of hypoglycemia
EP4545544A3 (en) Modified crispr rna and modified single crispr rna and uses thereof
WO2014052836A3 (en) Methods and compositions for treating infection
IL248959A0 (en) Preparations and methods for the treatment and prevention of staphylococcus aureus infections
EP3099298B8 (en) Zidovudine combination therapies for treating microbial infections
WO2015175977A3 (en) Antisense antibacterial compounds and methods
EP3569252A3 (en) Antisense antibacterial compounds and methods
WO2017059122A8 (en) Methods of treating and preventing amyotrophic lateral sclerosis
EP3119781A4 (en) Compounds which inhibit rna polymerase, compositions including such compounds, and their use
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
EP3584319A4 (en) SINGLE-STRAND OLIGONUCLEOTIDE
EP3268010A4 (en) Compositions and methods for treating bacterial infection
SMT201900692T1 (it) Composizione per l'uso del trattamento delle infezioni batteriche
EP3273797A4 (en) Composition inhibiting gram-positive, pathogenic bacteria
EP3190893A4 (en) Compositions and methods for treating and preventing bacterial infections
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
BR112014032290A2 (pt) composições e métodos para tratar ou prevenir infecção de pneumovírus e doenças associadas.
EP3231439A4 (en) Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia
WO2017100645A3 (en) Inhibitors of bacterial rna polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols
EP3220920A4 (en) Combination therapy effective against microorganisms, including drug resistant microorganisms